SR9009

SR9009, commonly called Stenabolic, is a REV-ERB agonist that influences metabolism and the body's circadian clock. While often grouped with SARMs, it works through a completely different, non-hormonal pathway. Its primary benefits are a dramatic increase in endurance and the promotion of fat loss.

What is SR9009?

SR9009 is a synthetic agonist that activates REV-ERB proteins, which play a key role in regulating circadian rhythm, metabolism, and inflammation. By modulating these pathways, it enhances the body's energy utilization and efficiency. It is not a SARM, as it does not interact with androgen receptors.

Stenabolic - SR9009 (Lean Muscle/Fat Loss) 10mg/50tabs - NEO Sarms

Stenabolic is a non-steroidal SARM, widely used for fat loss, lean muscle gains, and enhanced endurance. Works better for cutting cycles. Goals: substantial fat loss, muscle hardness, density and definition Administration: 30-40

$75.00

Add to Cart

4.9

Key Benefits and Effects

1. Dramatically Increases Endurance and Energy

SR9009 upregulates the production of new mitochondria (the powerhouses of cells) and improves their efficiency. This leads to:

• A significant boost in stamina and workout capacity.
• Shorter rest periods between sets and faster recovery.
• Increased overall daily energy levels without CNS stimulation (no jitters or crash).

2. Promotes Fat Loss

By activating REV-ERB, SR9009 shifts the body's energy metabolism to prioritize burning stored fat. This creates a powerful fat-loss effect, especially when combined with a calorie deficit and exercise. It helps maintain this fat-burning state throughout the day.

3. Supports Lean Muscle Preservation

The compound mimics certain genetic effects of exercise, helping to maintain or even slightly increase lean body mass during a cutting phase. It is not a mass-builder like anabolic steroids but supports an anti-catabolic environment.

4. Improifies Cholesterol Profiles

SR9009 has been shown to improve lipid metabolism, potentially lowering LDL ("bad") cholesterol and triglycerides while increasing HDL ("good") cholesterol. This is a valuable benefit for athletes using other compounds that may negatively affect lipids.

Critical Dosage and Administration Challenge

The original text significantly understates a major flaw: SR9009 has extremely poor oral bioavailability (estimated at <5%, not 24%). This means pills/capsules are largely ineffective.

Effective Protocol: To work, SR9009 must be administered sublingually (held under the tongue) or via transdermal solution. The dosing schedule is demanding due to a short half-life of ~4 hours.

Standard Dosage: 20-30 mg per day, split into 4-5 doses (e.g., 5-7mg every 4-5 hours), including one dose upon waking and one pre-workout.

SR9009 Stacks for Cutting and Performance

Due to its demanding dosing schedule, SR9009 is best stacked with complementary compounds that have longer half-lives to achieve synergistic effects.

SR9009 is non-hormonal and does not suppress the HPTA axis. Therefore, it does not require Post-Cycle Therapy (PCT) on its own. However, if stacked with suppressive compounds like SARMs or prohormones, a standard PCT (e.g., Tamoxifen) is required for those substances.

Side Effects and Safety

When used correctly, SR9009 is considered to have a minimal side effect profile due to its non-hormonal action. The most common "side effect" is the inconvenience of its dosing schedule. There is no evidence of liver toxicity, androgenic side effects, or estrogenic activity. Long-term human safety data is still lacking.

Conclusion

SR9009 is a unique, non-hormonal compound that can profoundly enhance endurance, metabolic rate, and fat loss. Its major limitation is its very poor oral bioavailability, requiring a strict sublingual or transdermal dosing protocol multiple times per day. It is most effective when stacked with longer-acting compounds like Cardarine for a powerful, stimulant-free cutting and endurance stack. For those willing to adhere to the precise dosing, it can be a game-changer for training performance and body composition.

1. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs
2. REV-ERB Agonist SR9009 Regulates the Proliferation and Neurite Outgrowth/Suppression of Cultured Rat Adult Hippocampal Neural Stem/Progenitor Cells in a Concentration-Dependent Manner